People on the Move
Avillion
Avillion, a late-stage CRO, has appointed Allison Jeynes-Ellis, previously of Wyeth, Bristol-Myers Squibb and Novartis, as CEO.
Jeynes-Ellis was previously the company’s Chief Medical Officer, and has held senior roles in the pharmaceutical industry for 20 years, as well as independent consulting positions at Genentech and with UK government bodies.
Avillion helps develop and finance drug candidates in their later stages, from Phase 3 trials to marketing approval.
Jeynes-Ellis said she aimed to speed up late-stage development in the role: “We are aiming to be a key partner to companies with promising late-stage clinical assets, which for reasons of funding or resource constraints are not being advanced as quickly as they could be.”
